S&P Futures
5,630.50 +0.75 (+0.01%) Dow Futures
41,462.00 +35.00 (+0.08%) Nasdaq Futures
19,523.25 -7.00 (-0.04%) Russell 2000 Futures
2,193.10 +8.30 (+0.38%) Crude Oil
68.93 +0.28 (+0.41%) Gold
2,609.10 -1.60 (-0.06%)
Kymera Therapeutics, Inc. (KYMR)
After hours:
| Previous Close | 44.72 |
| Open | 45.07 |
| Bid | 46.02 x 100 |
| Ask | 46.19 x 200 |
| Day's Range | 44.53 - 46.47 |
| 52 Week Range | 9.60 - 50.19 |
| Volume | |
| Avg. Volume | 575,456 |
| Market Cap | 2.976B |
| Beta (5Y Monthly) | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.41 |
| Earnings Date | Oct 31, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.73 |
ZacksWhy Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireKymera Therapeutics to Participate in Upcoming September Investor Conferences
WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 2024 Healthcare Conference in Boston, MA on September 4 at 3:00 p.m. ET;Morgan Stanley 22nd Annual Global Healthcare Conference in
- GlobeNewswire
Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera sold and issued 2,830,533 shares of
